13 results on '"Verweij, Jaap"'
Search Results
2. Cancer clinical trial outcomes: Any progress in tumour-size assessment?
- Author
-
Verweij, Jaap, Therasse, Patrick, and Eisenhauer, Elizabeth
- Subjects
- *
TECHNOLOGICAL innovations in cancer treatment , *HEALTH outcome assessment , *CLINICAL trials , *CANCER patients , *CANCER-related mortality ,WESTERN countries - Abstract
Abstract: Cancer for many patients is still a lethal disease, and we are at the edge of the time that it will be the leading cause of death in the western world. One of the hallmarks of cancer is its ability to spread to other organs, turning cancer in essence to a systemic disease. For this reason, systemic therapy plays an important role in our efforts to either obtain cure or to prolong life and palliate symptoms. The ultimate goal in the development of such new treatments is cure or prolongation of life, but the process to ascertain this may be lengthy. This presents a limitation to the rapid assessment of the potential benefit of new cancer treatments, which is why investigators and regulators have been interested in clinical trial measures that could provide early readouts of drug activity or efficacy, in other words for surrogate indicators for the ultimately desired outcome. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
3. Effects of St. John's Wort on Irinotecan Metabolism.
- Author
-
Mathijssen, Ron H.J., Verweij, Jaap, De Bruijn, Peter, Loos, Walter J., and Sparreboom, Alex
- Subjects
- *
HYPERICUM , *CANCER patients , *DRUG interactions - Abstract
Discusses results of a study on the effects of the herbal plant Saint John's wort (SJW) on irinotecan metabolism in cancer patients. Patient characteristics; Percent decrease of plasma levels of irinotecan, a prodrug of SN-38; Advice that cancer patients taking irinotecan refrain from taking SJW.
- Published
- 2002
- Full Text
- View/download PDF
4. Lifestyle habits as a contributor to anti-cancer treatment failure
- Author
-
de Jong, Floris A., Sparreboom, Alex, Verweij, Jaap, and Mathijssen, Ron H.J.
- Subjects
- *
CANCER treatment , *CANCER patients , *CIGARETTE smokers , *CHEMICAL kinetics - Abstract
Abstract: Lifestyle may have serious consequences for cancer treatment outcome, which is a fact that both physicians and patients are often not explicitly aware of, thereby unwillingly exposing the patient to possible danger. In certain cases, patient behaviour can lead to potentially life-threatening adverse events, whilst in other cases the clinical benefit of anti-cancer therapy can be diminished. In this review, we focus on the role of certain habits (like cigarette smoking, alcohol use and the use of complementary and alternative medicine) and discuss the effects they may have on anti-cancer medication. Also patient compliance to prescribed anti-cancer drugs is a factor frequently overlooked if treatment does not follow the expectations, which gains importance with the increasingly frequent prescription of oral anti-cancer agents. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
5. Role of pharmacogenetics in irinotecan therapy
- Author
-
de Jong, Floris A., de Jonge, Maja J.A., Verweij, Jaap, and Mathijssen, Ron H.J.
- Subjects
- *
CANCER treatment , *GENETIC polymorphisms , *CANCER patients , *MEDICAL genetics - Abstract
Abstract: In the treatment of advanced colorectal cancer, irinotecan has become one of the most important drugs, despite its sometimes unpredictable adverse effects. To understand why some patients experience severe adverse effects (diarrhea and neutropenia), while others do not, the metabolic pathways of this drug have to be unraveled in detail. Individual variation in expression of several phase I and phase II metabolizing enzymes and ABC-transporters involved in irinotecan metabolism and excretion, at least partly explains the observed pharmacokinetic interpatient variability. Although the difference in expression-level of these proteins to a certain amount is explained by physiologic and environmental factors, the presence of specific genetic determinants also does influence their expression and function. In this review, the role of genetic polymorphisms in the main enzyme-systems (carboxylesterase, cytochrome P450 3A, and uridine diphosphate-glucuronosyltransferase) and ABC-transporters (ABCB1, ABCC2, and ABCG2) involved in irinotecan metabolism, are discussed. Since at this moment the field of pharmacogenetics and pharmacogenomics is rapidly expanding and simultaneously more rapid and cost-effective screening methods are emerging, a wealth of future data is expected to enrich our knowledge of the genetic basis of irinotecan metabolism. Eventually, this may help to truly individualize the dosing of this (and other) anti-cancer agent(s), using a personal genetic profile of the most relevant enzymes for every patient. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
6. Recurrence of Melanoma Following T Cell Treatment: Continued Antigen Expression in a Tumor That Evades T Cell Recruitment.
- Author
-
Straetemans, Trudy, Berrevoets, Cor, Coccoris, Miriam, Treffers-Westerlaken, Elike, Wijers, Rebecca, Debets, Reno, Cole, David K, Sewell, Andrew K, Dardalhon, Valerie, Taylor, Naomi, and Verweij, Jaap
- Subjects
- *
MELANOMA , *T cells , *CANCER patients , *MAJOR histocompatibility complex , *CELL adhesion molecules , *HUMAN T cell receptors , *THERAPEUTICS - Abstract
Clinical therapy with T cells shows promise for cancer patients, but is currently challenged by incomplete responses and tumor relapse. The exact mechanisms that contribute to tumor relapse remain largely unclear. Here, we treated mouse melanomas with T cell receptor-engineered T cells directed against a human peptide-major histocompatibility complex antigen in immune-competent mice. T cells resulted in significant tumor regression, which was followed by relapse in about 80-90% of mice. Molecular analysis revealed that relapsed tumors harbored nonmutated antigen genes, not silenced by promoter methylation, and functionally expressed surface antigen at levels equal to nontreated tumors. Relapsed tumors resisted a second in vivo T cell treatment, but regained sensitivity to T cell treatment upon retransplantation in mice. Notably, relapsed tumors demonstrated decreased levels of CD8 T cells and monocytes, which were substantiated by downregulated expression of chemoattractants and adhesion molecules. These observations were confirmed when using T cells specific for a less immunogenic, endogenous mouse melanoma antigen. We conclude that tumors, when exposed to T cell treatment, can relapse without loss of antigen and develop a milieu that evades recruitment of effector CD8 T cells. Our findings support the concept to target the tumor milieu to aid T cell therapy in limiting tumor relapse [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study
- Author
-
Kitzen, Jos J., Puozzo, Christian, de Jonge, Maja J., Brandely, Maud, and Verweij, Jaap
- Subjects
- *
PHARMACOKINETICS , *DOSE-response relationship in biochemistry , *INTRAVENOUS therapy , *VINORELBINE , *CANCER patients , *LIVER function tests , *HEMATOLOGY , *DRUG toxicity - Abstract
Abstract: We studied the pharmacokinetic profile of weekly oral and intravenous vinorelbine in cancer patients with various degrees of hepatic function, and assessed an intra-patient comparison of the pharmacokinetics of i.v. versus oral vinorelbine. In this open-label study, patients were randomised to receive an initial dose of vinorelbine at day 1 by either i.v. or the oral route followed by a second dose on day 8 via the alternative route. A total of 16 patients were included, 12 patients received the planned two administrations. Toxicities were similar for all cohorts and were mainly of haematological and gastrointestinal origin. Pharmacokinetic analysis of both routes did not reveal any differences between cohort I and II. Based on these findings in patients with mild to moderate liver dysfunction no dose modifications of vinorelbine have to be taken into consideration. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
8. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
- Author
-
Sleijfer, Stefan, Ouali, Monia, van Glabbeke, Martine, Krarup-Hansen, Anders, Rodenhuis, Sjoerd, Le Cesne, Axel, Hogendoorn, Pancras C.W., Verweij, Jaap, and Blay, Jean-Yves
- Subjects
- *
CYCLOPHOSPHAMIDE , *CANCER chemotherapy , *SOFT tissue tumors , *HEALTH outcome assessment , *RETROSPECTIVE studies , *CANCER prognosis , *CANCER patients , *DOXORUBICIN , *TUMOR treatment - Abstract
Abstract: Background: Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients’ characteristics. As ifosfamide is frequently applied in first line systemic therapy, we aimed to establish prognostic and predictive factors for outcome to ifosfamide-based therapy. Methods: A retrospective, exploratory analysis was performed on data from 1337 advanced STS patients who received first-line ifosfamide-containing chemotherapy. For predictive factor analysis, 660 patients treated with doxorubicin monotherapy served as comparators. Results: Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma. For response, independent favourable prognostic factors were doxorubicin combined with ifosfamide, higher histological grade, and histology with synovial sarcoma patients having the highest chance to respond. Predictive factor analysis showed that compared to doxorubicin monotherapy, patients who benefited less from ifosfamide-based therapies were leiomyosarcoma patients in terms of OS, and patients with liposarcoma for response. No predictive factors were found for PFS. Conclusion: In this study, we established an independent set of prognostic and predictive factors for outcome to ifosfamide-based chemotherapy in advanced STS patients. This study provides important information for the interpretation and design of clinical trials for specific STS entities and may contribute to further treatment individualisation of advanced STS patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
9. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
- Author
-
Konings, Inge R. H. M., Engels, Frederike K., Sleijfer, Stefan, Verweij, Jaap, Wiemer, Erik A. C., and Loos, Walter J.
- Subjects
- *
CANCER patients , *PHARMACOKINETICS , *PHARMACOLOGY , *BLOOD plasma , *CHEMICAL kinetics - Abstract
To better understand the mechanisms underlying (in)sensitivity of tumors to anticancer drugs, assessing intra-tumor drug pharmacokinetics (PKs) could be important. We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug. Plasma and microdialysate samples from tumor and adipose normal tissues were collected up to 47 h after dosing in eight carboplatin-treated patients with an accessible (sub)cutaneous tumor. Pharmacokinetics were evaluable in tumor tissue in 6/8 patients and in adipose normal tissue in 3/8 patients. Concentration–time curves of unbound platinum in both the tissues followed the pattern of the curves in plasma, with exposure ratios of tissue versus plasma ranging from 0.64 to 1.46. Microdialysis can be successfully employed in ambulant patients for multiple days, which enables one to study tissue PK of anticancer drugs in normal and malignant tissues in more detail. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
10. Individual patient data analysis to assess modifications to the RECIST criteria
- Author
-
Bogaerts, Jan, Ford, Robert, Sargent, Dan, Schwartz, Lawrence H., Rubinstein, Larry, Lacombe, Denis, Eisenhauer, Elizabeth, Verweij, Jaap, and Therasse, Patrick
- Subjects
- *
CANCER patients , *MEDICAL records , *DATA analysis , *ONCOLOGY , *CLINICAL trials , *METASTASIS , *HEALTH outcome assessment - Abstract
Abstract: Background: After the initial RECIST 1.0 were published in 2000, the criteria were widely implemented in the scientific oncology community. Since then, the RECIST working group has identified several issues to examine further. Two key issues that required careful, data-based assessment were the maximum number of lesions that should be assessed at each evaluation and the added value of requiring confirmation of response. Methods: To address these questions, data were obtained from 16 clinical trials in metastatic cancer, with patients enrolled between 1993 and 2005. A total of 6512 patients were included in the primary analysis dataset, accounting for over 18,000 potential target lesions. Nine percent of the included patients (n =585) had six or more reported target lesions. The response and progression outcomes in the database were calculated using an adjusted RECIST methodology with a maximum of 5 (or 3) target lesions with/without confirmation and this was compared to the original RECIST version 1.0 which required up to 10 target lesions plus confirmation of response. Results: Assessment of 5 lesions per patient led to a difference in best overall response assignment for an estimated 209 (3.2%) patients as compared to RECIST version 1.0. However, these changes did not affect the overall response rate. Progression-free survival was only minimally affected by measuring fewer lesions. In contrast, removing the requirement for response confirmation led to a significant increase in the numbers of patients classified as responders, resulting in a relative increase of approximately 19% in response rate. An algorithm using a maximum of three target lesions shows high concordance with the 10 lesions requirement in terms of response and TTP assignment. Concern that appropriate assessment of disease within an organ requires two lesions to be followed per organ suggests the approach of following two target lesions per organ, up to a maximum of five target lesions overall. Both strategies seem reasonable based on the data warehouse. The requirement of response confirmation in trials where this is a primary end-point is recommended to be maintained as its removal would substantially increase reported response rates. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
11. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
- Author
-
Debiec-Rychter, Maria, Sciot, Raf, Le Cesne, Axel, Schlemmer, Marcus, Hohenberger, Peter, van Oosterom, Allan T., Blay, Jean-Yves, Leyvraz, Serge, Stul, Michel, Casali, Paolo G., Zalcberg, John, Verweij, Jaap, Van Glabbeke, Martine, Hagemeijer, Anne, and Judson, Ian
- Subjects
- *
DRUG therapy , *IMATINIB , *TUMORS , *ONCOLOGY , *CANCER patients , *CANCER treatment - Abstract
Abstract: A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival. The current analysis of that study aimed to assess if tumour mutational status correlates with clinical response to imatinib. Pre-treatment samples of GISTs from 377 patients enrolled in phase III study were analyzed for mutations of KIT or PDGFRA by combination of D-HPLC and direct sequencing of tumour genomic DNA. Mutation types were correlated with patients’ survival data. The presence of exon 9-activating mutations in KIT was the strongest adverse prognostic factor for response to imatinib, increasing the relative risk of progression by 171% (P <0.0001) and the relative risk of death by 190% (P <0.0001) when compared with KIT exon 11 mutants. Similarly, the relative risk of progression was increased by 108% (P <0.0001) and the relative risk of death by 76% (P =0.028) in patients without detectable KIT or PDGFRA mutations. In patients whose tumours expressed an exon 9 KIT oncoprotein, treatment with the high-dose regimen resulted in a significantly superior progression-free survival (P =0.0013), with a reduction of the relative risk of 61%. We conclude that tumour genotype is of major prognostic significance for progression-free survival and overall survival in patients treated with imatinib for advanced GISTs. Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800mg daily dose of the drug. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
12. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
- Author
-
Planting, André, van der Gaast, Ate, Schoöffski, Patrick, Bartkowski, Michele, Verheij, Coleta, Noe, Dennis, Ferrante, Karen, and Verweij, Jaap
- Subjects
- *
EXPERIMENTAL pharmacology , *METALLOPROTEINASES , *CANCER patients , *CLINICAL drug trials , *CANCER invasiveness , *PHARMACOLOGY - Abstract
Background: Matrix metalloproteinases play a role in the process of tissue invasion and metastasis by degrading the extracellular matrix. Inhibitors of matrix metalloproteinases are therefore of interest as anticancer drugs. CP-471,358 is a matrix metalloproteinase inhibitor that in vitro demonstrates strong inhibition of matrix metalloproteinases 2 and 9. The drug can be administered orally without food restriction. Study design: An open-label phase I study was performed in patients with advanced solid tumors to assess the safety, tolerability, maximal tolerated dose (MTD) and pharmacokinetics of CP-471,358. The CP-471,358 doses studied were 50, 100 and 200 mg three times daily (TID) continuously, 50, 100 and 200 mg TID for 21 days followed by a 1-week treatment-free interval and 75 mg and 150 mg twice daily (BID) continuously. Results: A total of 38 patients were treated in the study. The median number of cycles administered was two (range one to five). Myalgia and arthralgia were the most frequently observed adverse events (in 27 of 38 patients) and were observed at all dose levels and with all schedules except for the 150 mg BID continuous dosing level. In six patients National Cancer Institute (NCI) Common Toxicity Criteria (CTC) grade 3 myalgia/arthralgia was observed and this adverse event was considered to be the dose-limiting toxicity (DLT). Introduction of a 1-week treatment-free interval between cycles had no effect on the occurrence of myalgia/arthralgia. After cessation of treatment, arthralgia/myalgia was reversible in all patients. Other adverse events observed were fatigue and an increase of liver enzymes but these rarely exceeded CTC grade 2. Pharmacokinetic analysis showed that target efficacious concentrations were achieved throughout the morning dosing interval with 150 mg BID and 200 mg TID. Conclusion: The DLT of CP-471,358 was myalgia and arthralgia, an adverse event observed during treatment with most matrix metalloproteinase inhibitors. A drugfree interval of 1 week was unable to prevent the occurrence of these adverse effects. Clearly this represents a limitation for potential long-term use of this compound. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
13. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe.
- Author
-
Uyl-de Groot, Carin A., Heine, Renaud, Krol, Marieke, and Verweij, Jaap
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER patients , *MEDICAL records , *TUMORS , *DRUG approval , *RETROSPECTIVE studies , *IPILIMUMAB , *DESCRIPTIVE statistics , *INVESTIGATIONAL drugs , *ABIRATERONE acetate , *ACQUISITION of data methodology - Abstract
Background. Many new cancer medicines have been developed that can improve patients' outcomes. However, access to these agents comes later in Europe than in the United States (US). The aim of this study is to assess the access in Europe to newly registered cancer drugs and to get more insight in the implications of these variations for patients. Methods. A retrospective database study was conducted. Analyses involved 12 cancer drugs and 28 European countries in the period 2011–2018. Time to patient access, speed of drug uptake, and the potential loss of life years due to a delay in access have been studied. Results. Marketing approval for the cancer drugs came on average 242 days later in Europe than in the US, and actual patient access varied extensively across Europe. The average time to market in Europe was 403 days (range 17–1187 days). The delay in patient access of ipilimumab and abiraterone may have led to a potential loss of more than 30,000 life years. Conclusion. It takes a long time for patients to get access to newly registered cancer drugs and there is great variation in access. The health outcomes can be substantially improved by faster processes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.